

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE SIX MONTHS ENDED 30 JUNE 2023

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “**Company**”) dated 28 August 2023 (the “**Announcement**”) in relation to the 2023 interim report of China National Accord Medicines Corporation Ltd. (“**Sinopharm Accord**”), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited accounting data and financial indicators of Sinopharm Accord for the six months ended 30 June 2023 (the “**Reporting Period**”) as set out in the Announcement.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD

Whether it has retroactive adjustment or restatement on previous accounting data or not

Yes No

Reasons for retroactive adjustment or restatement

Other reasons

*Unit: Yuan
Currency: RMB*

	The Reporting Period	Same period of last year		Changes of this period over the same period of last year After adjustment
		Before adjustment	After adjustment	
Revenue	38,387,531,548.02	36,128,910,049.98	36,128,910,049.98	6.25%
Net profit attributable to shareholders of the listed company	830,251,088.20	674,215,912.93	674,215,912.93	23.14%
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	794,646,271.22	652,857,302.76	652,857,302.76	21.72%
Net cash flow arising from operating activities	1,486,276,000.93	1,041,664,059.17	1,041,664,059.17	42.68%
Basic earnings per share (Yuan/Share)	1.49	1.57	1.21	23.14%
Diluted earnings per share (Yuan/Share)	1.49	1.57	1.21	23.14%
Weighted average return on net assets	5.04%	4.44%	4.44%	Increased by 0.60 percentage point

	At the end of the Reporting Period	At the end of last year		Changes of this period-end over the end of last year After adjustment
		Before adjustment	After adjustment	
Total assets	49,882,938,760.59	42,615,760,577.42	42,615,760,577.42	17.05%
Net assets attributable to shareholders of listed company	16,613,532,160.81	16,125,890,447.68	16,125,890,447.68	3.02%

By order of the Board
Sinopharm Group Co. Ltd.
Yu Qingming
Chairman

Shanghai, the PRC
28 August 2023

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Ma Ping, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.